Compare Adaptive Biotechnologies Corp (ADPT) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lumen Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Lumen Technologies Inc trades at $6.47 (market cap $6.64B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | LUMN | |
|---|---|---|
Market Cap | $3.33B | $6.64B |
Sector | Health | Media |
52-Week High | $22.37 | $11.83 |
52-Week Low | $10.24 | $3.70 |
Enterprise Value | $3.19B | $18.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LUMN trades at $6.44, up 0.16% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $1.74B in 2025, though it beat EPS estimates in two of the last three quarters. Recent news highlights the completion of the Alkira acquisition, aimed at boosting its AI-era networking capabilities. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a negative net income margin of -14.34%.
The outlook remains challenging due to persistent losses and high debt, but strategic acquisitions and a 15% forward free cash flow yield offer potential upside. Risks include execution hurdles in integrating acquisitions and intense telecom competition. Analyst consensus is a Hold with a $8.25 price target, suggesting cautious optimism amid fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
